Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide

    PT-141 (Bremelanotide) vs Melanotan II

    Independent, side-by-side comparison of PT-141 (Bremelanotide) and Melanotan II: mechanism, half-life, dose range, safety profile, and live vendor pricing. Updated continuously as new research and listings land.

    PT-141 (Bremelanotide) from $29.99
    Melanotan II from $34.99

    Live price snapshot

    PT-141 (Bremelanotide)

    Current low
    $37.00
    as of Apr 22, 2026
    7-day low
    $37.00
    30-day low
    $34.99
    30-day change
    baseline building

    Melanotan II

    Current low
    $67.00
    as of Apr 22, 2026
    7-day low
    $35.00
    30-day low
    $34.99
    30-day change
    baseline building

    PT-141 (Bremelanotide)

    PT-141 (bremelanotide) is a cyclic 7-amino-acid synthetic melanocortin receptor agonist that acts centrally in the brain — not peripherally on genital tissue — to enhance sexual desire, arousal, and responsiveness. It is…

    Live lowest price: $29.99 across 7 vendors

    Full PT-141 (Bremelanotide) profile

    Melanotan II

    Melanotan-II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (╬▒-MSH) engineered in the late 1980s by researchers at the University of Arizona, most prominently Mac Hadley and…

    Live lowest price: $34.99 across 5 vendors

    Full Melanotan II profile

    Side-by-side comparison

    Attribute PT-141 (Bremelanotide) Melanotan II
    Category Skin, Hair & Aesthetics Skin, Hair & Aesthetics
    Research Stage FDA Approved Preclinical
    Mechanism of Action Melanocortin Receptor Pharmacology PT-141 is a synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-DPhe-Arg-Trp-Lys]-OH) that binds the melanocortin receptor family with the following selectivity profile: | Receptor | Primary Location | PT-141 Activity |… Melanotan-II works by binding to and activating all four G-protein-coupled melanocortin receptors expressed in mammalian tissue (MC1R, MC3R, MC4R, MC5R — MC2R responds only to ACTH), with particularly high affinity at MC1R, MC3R, and MC4R. Melanocortin…
    Half-Life ~2 hours
    Typical Dose Range 500–2,000 mcg (0.5–2 mg) per dose
    Dosing Frequency As needed, 45 minutes before sexual activity; max once per 24 hours, max 8 doses/month
    Administration Subcutaneous
    Side Effects Very Common (10% of users) - Nausea — By far the most common adverse effect, affecting approximately 40% of users in the RECONNECT trials. Usually mild-to-moderate, begins within 30-60 minutes of injection, resolves within 2-4 hours. Can be mitigated with… The side-effect profile of MT-II is dose-dependent and largely driven by pan-melanocortin receptor activation. Many users experience the acute side effects as more limiting than the tanning benefit. Very Common (50% of users): - Nausea — the single most common…
    Molecular Weight 1025.2 Da 1024.19 g/mol
    Common Vial Sizes 2mg, 10mg

    Price History

    5 data points
    • OF
    • Unknown
    • Nova Peptides
    • VANDL Labs
    • Adera
    • Ion Peptide

    Price History

    3 data points
    • VANDL Labs
    • Adera
    • Ion Peptide

    PT-141 (Bremelanotide) — potential benefits

    • Sexual desire enhancement
    • HSDD treatment
    • Erectile dysfunction (central mechanism)
    • Non-hormonal approach

    Melanotan II — potential benefits

    • Tanning without UV
    • Appetite suppression
    • Sexual arousal
    • Photoprotection
    • Fat loss

    Frequently asked

    What's the difference between PT-141 (Bremelanotide) and Melanotan II?

    PT-141 (Bremelanotide) is a skin, hair & aesthetics that melanocortin receptor pharmacology pt-141 is a synthetic cyclic heptapeptide (ac-nle-cyclo[asp-his-dphe-arg-trp-lys]-oh) that binds the melanocortin receptor family with the…. Melanotan II is a skin, hair & aesthetics that melanotan-ii works by binding to and activating all four g-protein-coupled melanocortin receptors expressed in mammalian tissue (mc1r, mc3r, mc4r, mc5r — mc2r responds only to…. The two differ in mechanism, half-life (~2 hours vs not reported), and typical dose range.

    Which has the longer half-life, PT-141 (Bremelanotide) or Melanotan II?

    PT-141 (Bremelanotide) has a half-life of ~2 hours. Melanotan II has a half-life of not reported. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.

    Which is cheaper, PT-141 (Bremelanotide) or Melanotan II?

    Current lowest live price on BodyHackGuide: PT-141 (Bremelanotide) from $29.99, Melanotan II from $34.99. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers.

    Can you stack PT-141 (Bremelanotide) and Melanotan II?

    Stacking depends on mechanism overlap, safety profile, and goals. PT-141 (Bremelanotide) and Melanotan II should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.

    See current vendor prices

    Live listings from the vendors we track, refreshed continuously.

    PT-141 (Bremelanotide) prices Melanotan II prices Compare all compounds

    Related comparisons

    Melanotan I vs Melanotan IiGHK CU vs AHK CU

    Research use only. BodyHackGuide is an independent research reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks — this never affects the data or pricing shown. See editorial standards and affiliate disclosure.